- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. Provided by PR Newswire Apr 29, 2025, 4:32:00 PM ...

FDA approval for ZEVASKYN underscores its significance as a groundbreaking treatment in the field of gene therapy, enhancing Abeona’s position in the biopharmaceutical market.

The FDA approval of ZEVASKYN is based on the pivotal Phase 3 VIITAL™ study (NCT04227106), a multi-center, randomized, intrapatient-controlled trial that met its two co-primary efficacy endpoints ...

MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN ...

FDA approval of Zevaskyn was based on findings from two clinical studies. In a single-center, open-label, phase 1/2a study involving 38 chronic wounds in seven patients, a single surgical ...

Abeona Therapeutics enters Q2 2025 as a commercial-stage company with ZEVASKYN FDA approval, first patient site activation, and a $155 million PRV sale supporting a cash runway toward projected ...

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin’) ...